
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the topline results for RSVP clinical study evaluating EDP-938, in otherwise healthy adults with community-acquired Respiratory Syncytial Virus (RSV).
The phase 2b RSVP clinical study evaluating EDP-938 did not meet the primary endpoint of reduction in total symptom score compared to placebo, or the secondary antiviral endpoints.